NCT03719820 (SIPS-ICAS) is a clinical trial of aggressive medical management in Acute Ischemic Stroke AIS, sponsored by Wei-Hai Xu.

Who is sponsoring NCT03719820?

NCT03719820 is sponsored by Wei-Hai Xu.

What drugs are being tested in NCT03719820?

Interventions in NCT03719820: aggressive medical management.

What condition does NCT03719820 study?

NCT03719820 studies Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS.

Is NCT03719820 still recruiting?

NCT03719820 is currently status unknown. Last updated 31 March 2020.

Last reviewed 2020-03-31 · How we verify

NCT03719820: SIPS-ICAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stroke Imaging Package Study of Intracranial Atherosclerosis ( SIPS-ICAS )

Status unknown Last updated 31 March 2020

What this trial tests

trial testing aggressive medical management in Acute Ischemic Stroke AIS in 550 participants. Status unknown.

Timeline

14 November 2018

Primary endpoint
31 December 2020

30 June 2021

Quick facts

Lead sponsor	Wei-Hai Xu
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	550
Start date	14 November 2018
Primary completion	31 December 2020
Estimated completion	30 June 2021
Sites	38 locations across China

Drugs / interventions tested

aggressive medical management — full drug profile →

Conditions studied

Acute Ischemic Stroke AIS — all drugs for Acute Ischemic Stroke AIS →
Intracranial Atherosclerosis ICAS — all drugs for Intracranial Atherosclerosis ICAS →

Sponsor

Wei-Hai Xu

Who can join

Adults 35 to 80, any sex, with Acute Ischemic Stroke AIS or Intracranial Atherosclerosis ICAS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, multicenter, cohort study to explore the stroke mechanisms of symptomatic intracranial atherosclerosis, the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus high-resolution magnetic resonance (HR-MRI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Ischemic Stroke AIS

Currently open trials in the same condition.

NCT07052045 — One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy · NA · recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT07084012 — A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS · Phase 2 · recruiting
NCT06320431 — ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 · Phase 3 · recruiting
NCT06052969 — Pulse Endovascular ReperFUSION for Acute Ischemic Stroke · NA · recruiting

Other Wei-Hai Xu trials

Trials by the same sponsor.

NCT02485275 — Stroke Imaging Package Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03719820 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wei-Hai Xu
Last refreshed: 31 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03719820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing